Carbapenem-resistant Clinical Trials

9 recruitingLast updated: May 13, 2026

There are 9 actively recruiting carbapenem-resistant clinical trials across 8 countries. Studies span Not Applicable, Phase 4. Top locations include Fuzhou, Fujian, China, Hefei, Anhui, China, Hong Kong, Shatin, Hong Kong. Updated daily from ClinicalTrials.gov.


Carbapenem-resistant Trials at a Glance

9 actively recruiting trials for carbapenem-resistant are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Not Applicable with 4 trials, with the heaviest enrollment activity in Fuzhou, Hefei, and Hong Kong. Lead sponsors running carbapenem-resistant studies include Chinese University of Hong Kong, Chuncheon Sacred Heart Hospital, and Children's Hospital of Fudan University.

Browse carbapenem-resistant trials by phase

Treatments under study

About Carbapenem-resistant Clinical Trials

Looking for clinical trials for Carbapenem-resistant? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Carbapenem-resistant trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Carbapenem-resistant clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 4

Different Administration Regimens of CAZ-AVI in Combination With ATM for the Treatment of CR-GNB

Ceftazidime-avibactamAztreonamGram-negative Bacterial Infection+2 more
Jing Zhou144 enrolled1 locationNCT07478484
Recruiting

Risk Factors for Colonization or Infection With Carbapenem-Resistant Enterobacteriaceae in Children

Carbapenem-Resistant Enterobacteriaceae Infection
Children's Hospital of Fudan University536 enrolled1 locationNCT04535661
Recruiting

Different Methods of Aerosolized Polymyxin B Inhalation for Treating Carbapenem-Resistant Gram-Negative Bacterial Pneumonia.

Carbapenem-Resistant Enterobacteriaceae InfectionPneumonia, Bacterial
Fujian Medical University Union Hospital144 enrolled1 locationNCT07086391
Recruiting
Not Applicable

Interventions to Decrease CRE Colonization and Transmission Between Hospitals, Households, Communities and Domesticated Animals

Antibiotic Resistant InfectionCarbapenem-Resistant Enterobacteriaceae Infection
Hanoi University of Public Health800 enrolled1 locationNCT05871476
Recruiting
Not Applicable

Efficacy and Safety of FMT for the Decolonization of MDROs in the Intestinal Tract

Carbapenem-Resistant EnterobacteriaceaeVancomycin (Glycopeptide) Resistant Enterococcus (VRE)
Chuncheon Sacred Heart Hospital240 enrolled2 locationsNCT06001333
Recruiting
Not Applicable

Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection

Carbapenem-Resistant Enterobacteriaceae Infection
Southeast University, China404 enrolled15 locationsNCT06051513
Recruiting
Not Applicable

Safety and Efficacy of Fecal Microbiota Transplantation

AlopeciaDiabetes MellitusObesity+24 more
Chinese University of Hong Kong450 enrolled1 locationNCT04014413
Recruiting
Phase 4

EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics

Hospital-Acquired PneumoniaHealthcare associated infectionCarbapenem-Resistant Enterobacteriaceae Infection+2 more
National University of Singapore1,900 enrolled4 locationsNCT05979545
Recruiting

Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients

Antibiotic Resistant InfectionCarbapenem-Resistant Enterobacteriaceae InfectionVancomycin Resistant Enterococci Infection+5 more
The Methodist Hospital Research Institute1,000 enrolled2 locationsNCT06258551